Literature DB >> 35859135

The cell-line-derived subcutaneous tumor model in preclinical cancer research.

Stephen M Stribbling1, Anderson J Ryan2.   

Abstract

Tumor-bearing experimental animals are essential for preclinical cancer drug development. A broad range of tumor models is available, with the simplest and most widely used involving a tumor of mouse or human origin growing beneath the skin of a mouse: the subcutaneous tumor model. Here, we outline the different types of in vivo tumor model, including some of their advantages and disadvantages and how they fit into the drug-development process. We then describe in more detail the subcutaneous tumor model and key steps needed to establish it in the laboratory, namely: choosing the mouse strain and tumor cells; cell culture, preparation and injection of tumor cells; determining tumor volume; mouse welfare; and an appropriate experimental end point. The protocol leads to subcutaneous tumor growth usually within 1-3 weeks of cell injection and is suitable for those with experience in tissue culture and mouse experimentation.
© 2022. Springer Nature Limited.

Entities:  

Mesh:

Year:  2022        PMID: 35859135     DOI: 10.1038/s41596-022-00709-3

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   17.021


  130 in total

Review 1.  New cast for a new era: preclinical cancer drug development revisited.

Authors:  Grit S Herter-Sprie; Andrew L Kung; Kwok-Kin Wong
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

Review 2.  Tumor models for efficacy determination.

Authors:  Beverly A Teicher
Journal:  Mol Cancer Ther       Date:  2006-10       Impact factor: 6.261

3.  Establishment of human tumor xenografts in immunodeficient mice.

Authors:  Christopher L Morton; Peter J Houghton
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

Review 4.  Mouse modeling in oncologic preclinical and translational research.

Authors:  Brett S Carver; Pier P Pandolfi
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

Review 5.  Influence of tumour micro-environment heterogeneity on therapeutic response.

Authors:  Melissa R Junttila; Frederic J de Sauvage
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

Review 6.  Contemporary pre-clinical development of anticancer agents--what are the optimal preclinical models?

Authors:  Giovanna Damia; Maurizio D'Incalci
Journal:  Eur J Cancer       Date:  2009-09-15       Impact factor: 9.162

Review 7.  Preclinical mouse solid tumour models: status quo, challenges and perspectives.

Authors:  Nicolas Gengenbacher; Mahak Singhal; Hellmut G Augustin
Journal:  Nat Rev Cancer       Date:  2017-10-27       Impact factor: 60.716

8.  Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors.

Authors:  Hashmat Sikder; David L Huso; Hong Zhang; Binghe Wang; Byungwoo Ryu; Sam T Hwang; Jonathan D Powell; Rhoda M Alani
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

9.  Trends in the lifetime risk of developing cancer in Great Britain: comparison of risk for those born from 1930 to 1960.

Authors:  A S Ahmad; N Ormiston-Smith; P D Sasieni
Journal:  Br J Cancer       Date:  2015-02-03       Impact factor: 7.640

Review 10.  The role of mouse tumour models in the discovery and development of anticancer drugs.

Authors:  Christopher R Ireson; Mo S Alavijeh; Alan M Palmer; Emily R Fowler; Hazel J Jones
Journal:  Br J Cancer       Date:  2019-06-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.